|
|
Dr. Durie - An Overview of the 49th Annual American Society of Hematology Meeting (ASH) 2007
Dr. Brian G.M. Durie
Cedars Sinai Cancer Center
Los Angeles, California
|
|
|
12.13.07 |
|
"This has been a great ASH for myeloma patients, so much new data has been presented."
Dr. Brian Durie
To view the video full screen, click on the small  button next to the volume control in the lower right hand corner.
|
 related articles |
Elijah Alexander: ASH 2007: A Patient's Perspective
Dr. Kyle: An Overview of the 49th Annual American Society of Hematology Meeting (ASH) 2007
Dr. Durie: An Overview of the 49th Annual American Society of Hematology Meeting (ASH) 2007
Dr. San Miguel: A Review of Novel Agents Presented at the 49th Annual American Society of Hematology Meeting (ASH) 2007
Dr. Gertz - An Overview of the 49th Annual American Society of Hematology Meeting (ASH) 2007
Dr. Jagannath: ASH 2007: New Drug Combinations as Induction Therapy
Dr. Boccadoro - An Overview of the 49th Annual American Society of Hematology Meeting (ASH) 2007
ASH 2007 INTERNATIONAL WEBCASTS
Dr. San Miguel - A Phase 3 Study Comparing BortezomibMelphalanPrednisone (VMP) with MelphalanPrednisone (MP) in Newly Diagnosed Multiple Myeloma.
Dr. Rajkumar - A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group
Dr. Richardson - Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Resultsof a Phase 1/2 Study.
Dr. Kumar - Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma
Dr. Palumbo - Bortezomib, Pegylated-Lyposomal-Doxorubicin and Dexamethasone Followed by Melphalan 100 mg/m in Elderly Newly Diagnosed Patients: An Interim Analysis
Dr. Palumbo - A Prospective, Randomized, Phase III Study of Enoxaparin Versus Aspirin Versus Low-Fixed-Dose of Warfarin in Newly Diagnosed Myeloma Patients Treated with Thalidomide-Containing Regimens
Dr. Jagannath - A Phase II Study of Bortezomib (Velcade®), Cylophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma
Dr. Reeder - Phase II Trial of Myeloma Induction Therapy with Cyclophosphamide, Bortezomib, and Dexamethasone (Cybor-D): Improved Response over Historical Lenalidomide-Dexamethasone Controls
Dr. Ludwig - Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment in Elderly Patients with Multiple Myeloma
Dr. Zonder - Superiority of Lenalidomide (Len) Plus High-Dose Dexamethasone (HD) Compared to HD Alone as Treatment of Newly-Diagnosed Multiple Myeloma (NDMM): Results of the Randomized, Double-Blinded, Placebo-Controlled SWOG Trial S0232
Dr. Waage - Melphalan-Prednisone-Thalidomide to Newly Diagnosed Patients with Multiple Myeloma: A Placebo Controlled Randomised Phase 3 Trial
Dr. San Miguel - Dexamethasone Dose Adjustments Seem To Result in Better Efficacy and Improved Tolerability in Patients with Relapsed/Refractory Multiple Myeloma Who Are Treated with Lenalidomide/Dexamethasone (MM009/010 Sub-Analysis)
Dr. Jagannath - Updated Survival Analyses after Prolonged Follow-Up of the Phase 2, Multicenter CREST Study of Bortezomib in Relapsed or Refractory Multiple Myeloma
Dr. Bladé - The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure
Dr. Davies - The Combination of Velcade, Idarubicin and Melphalan (VIM) Demonstrates Significant Clinical Activity in Relapsed/Refractory Myeloma Patients
Dr. Orlowski: Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma
Dr. Jakubowiak - A Multiple Myeloma Research Consortium (MMRC) Multicenter Phase I Trial of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM): Updated Results
Dr. Richardson - Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation
Dr. Orlowski - Safety and Antitumor Efficacy of the Proteasome Inhibitor Carfilzomib (PR-171) Dosed for Five Consecutive Days in Hematologic Malignancies: Phase 1 Results
Dr. Ocio - Antimyeloma Efficacy of Plitidepsin (Aplidin): From Bench to the Bedside
Dr. Richardson - An Overview of Studies of the New Agent Perifosine (KRX-0401) Alone and in Combination for Patients with Relapsed/Refractory Multiple Myeloma
Dr. Richardson - Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma
Dr. Ocio - Triple Combinations of the HDAC Inhibitor Panobinostat (LBH589) + Dexamethasone with Either Lenalidomide or Bortezomib Are Highly Effective in a Multiple Myeloma Mouse Model
Dr. Dispenzieri - Pre-Clinical Data and Preliminary Patient Results of Intravenous MV-NIS To Treat Relapsed, Refractory Multiple Myeloma
Dr. Davies - Aminopeptidase Inhibition as a Targeted Treatment Strategy in Myeloma
Dr. Zonder - Phase I Trial of HuLuc63 in Multiple Myeloma
Dr. Aggarwal: Curcumin downregulates NF-kB and related genes in patients with multiple myeloma: Results of a phase 1/2 study
Dr. Harousseau - VELCADE/Dexamethasone (Vel/D) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantion (ASCT) in Newly Diagnosed Multiple Myeloma (MM): Updated Results of the IFM 2005/01 Trial
Dr. Bruno - An Update of a Comparison of Nonmyeloablative Allografting with Autografting for Newly Diagnosed Myeloma
Dr. Hajek - Consolidation Therapy Based on Conventional Chemotherapy and Corticoids Do Not Provide Therapeutic Advantage for Newly Diagnosed Patients after Autologous Transplantation
Dr. Tosi - Superiority of Double over Single Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma and Prognostic Impact of Complete Response: Final Analysis of Bologna 96 Study
Dr. Beksac - Amplitude of Response, Early Mobilization (M) and Pre-Autologous Transplant (ASCT) Use of Bortezomib (V) and/or Thalidomide(T) Are Predictors of Longer Progression Free (PFS) and/or Overall Survival (OS) in Myeloma
Dr. Ladetto - Consolidation with Bortezomib, Thalidomide and Dexamethasone Induces Molecular Remissions in Autografted Multiple Myeloma Patients
Dr. Tosi - Bortezomib (Velcade)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) in Preparation for Autologous Stem-Cell (SC) Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma
Dr. De la Rubia - Toxicity and Early Response after Single Daily Dose of Intravenous Busulfan and Melphalan as Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. Session Type: Publication Only
Dr. Bladé - Tandem Autologous Transplant Versus Reduced Intensity Conditioned Allogeneic Transplant (Allo-RIC) as Second Intensification in Chemosensitive Patients with Multiple Myeloma (MM) Not Achieving Complete Remission (CR) or Near-CR with a First Autologous Transplant. Results from a Spanish PETHEMA/GEM Study.
Dr. Einsele - An Overview of Two Studies Conducted at the University Clinic of Würzburg
Dr. Liebisch - Prognostic Impact of Chromosomal Abnormalities in Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation
Dr. Avet-Loiseau - High-Resolution Genomic Profiles Identify Novel Genes and/or Chromosomal Regions with Prognostic and Oncogenic Significance in Myeloma Patients
Dr. Sezer - The Bone Resorption Marker Serum-ICTP and the Circulating Proteasome Levels Separate ISS-Stages 1-3 and Are the Most Powerful Prognostic Factors for Overall Survival in Newly Diagnosed Symptomatic Multiple Myeloma
Dr. Durie - Genetic Polymorphisms Identify the Likelihood of Bone Disease in Myeloma: Correlations with Myeloma Cell DKK1 Expression and High Risk Gene Signatures.
Dr. Kyle - Monoclonal Gammopathy of Undetermined Significance: Estimated Incidence and Duration Prior to Recognition
Dr. Kumar - Improving Survival in Multiple Myeloma: Impact of Novel Therapies
Dr. Jakubowiak - Targeted Therapy Against Clonogenic Myeloma Cells with Iodine I-131 Tositumomab (Bexxar™).
Dr. Kyle - Prognostic Value of the Serum Free Light Chain Ratio in Patients with Newly Diagnosed Myeloma: Proposed Incorporation into the International Staging System.
Dr. Goldschmidt - Angiogenic Signature of Multiple Myeloma Determined by Gene Expression Profiling
ASH Overview
|
|
|
Elijah Alexander
Former NFL lineman and Myeloma Patient shares his reactions on attending ASH for the first time |
|
|
|
|
Dr. Robert Kyle
Mayo Clinic
Rochester, Minnesota
Chair, IMF Scientific Advisory Board
|
|
|
|
|
Dr.Brian G.M. Durie
Cedars Sinai Cancer Center
Los Angeles, California
Chair of the International Myeloma Foundation
|
|
|
|
|
Dr. Jesús San Miguel
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain
Member, IMF Board of Scientific Advisors
|
|
|
|
|
Morie A Gertz, MD
Mayo Clinic
Rochester, Minnesota
Member, IMF Board of Scientific Advisors
|
|
|
|
|
Sundar Jagannath, MD
St. Vincent's Comprehensive Cancer Center
New York, NY
Member, IMF Board of Scientific Advisors
|
|
|
|
|
Mario Boccadoro, MD
Divisione Universitaria di Ematologia
Ospedale Molinette
Torino, Italy
Member, IMF Board of Scientific Advisors
|
|
|
|
|
We are pleased to be able to present overviews of ASH 2007 in French, Spanish, German, Italian, Turkish, and Czech. |
|
Newly Diagnosed Myeloma
|
|
|
Dr. Jesús San Miguel
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain
Member, IMF Board of Scientific Advisors
|
|
|
|
|
S. Vincent Rajkumar, MD
Mayo Clinic
Rochester, Minnesota
Member, IMF Board of Scientific Advisors
|
|
|
|
|
Paul Richardson, MD
Jerome Lipper Myeloma Center
Dana Farber Cancer Institute
Boston, MA
Member, IMF Board of Scientific Advisors
|
|
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, MN
|
|
|
|
|
Antonio Palumbo, MD
Ospedale Molinette
Torino, Italy
Member,IMF Board of Scientific Advisors
|
|
|
|
|
Antonio Palumbo, MD
Ospedale Molinette
Torino, Italy
Member,IMF Board of Scientific Advisors
|
|
|
|
|
Sundar Jagannath, MD
St. Vincent's Comprehensive Cancer Center
New York, New York
Member, IMF Board of Scientific Advisors
|
|
|
|
|
Craig B. Reeder, MD
Mayo Clinic
Scottsdale, Arizona
|
|
|
|
|
Heinz Ludwig, MD
Wilhelminenspital der Stadt Wein
Vienna, Austria
Member, IMF Board of Scientific Advisors
|
|
|
|
|
Jeffrey A. Zonder, MD
Karmanos Cancer Institute
Detroit, Michigan
|
|
|
|
|
Anders Waage, MD
University Hospital
Trondheim, Norway
|
|
Relapsed/Refractory Myeloma
|
|
|
Jesús San Miguel, MD
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain
Member, IMF Board of Scientific Advisors
|
|
|
|
|
Sundar Jagannath, MD
St. Vincent's Comprehensive Cancer Center
New York, NY
Member, IMF Board of Scientific Advisors
|
|
|
|
|
Joan Bladé, MD
Hospital Clinic
Hematology
Barcelona, Spain
Member, IMF Board of Scientific Advisors
|
|
|
|
|
Faith E. Davies, MD
The Royal Marsden NHS Foundation Trust
Sutton, Surrey, UK
Member, IMF Board of Scientific Advisors
|
|
|
|
|
Robert Z. Orlowski, MD
MD Anderson Cancer Center
Houston, Texas
|
|
|
|
|
Andrzej Jakubowiak, MD
University of Michigan Cancer Center
Ann Arbor, MI
|
|
New Agents
|
|
|
Paul Richardson, MD
Jerome Lipper Myeloma Center
Dana Farber Cancer Institute
Boston, MA
Member, IMF Board of Scientific Advisors
|
|
|
|
|
Robert Z. Orlowski, MD
MD Anderson Cancer Center
Houston, Texas
|
|
|
|
|
Enrique M. Ocio, MD
Hospital Universitario de Salamanca
Salamanca, Spain
|
|
|
|
|
Paul Richardson, MD
Jerome Lipper Myeloma Center
Dana Farber Cancer Institute
Boston, MA
Member, IMF Board of Scientific Advisors
|
|
|
|
|
Paul Richardson, MD
Jerome Lipper Myeloma Center
Dana Farber Cancer Institute
Boston, MA
Member, IMF Board of Scientific Advisors
|
|
|
|
|
Enrique M. Ocio, MD
Hospital Universitario de Salamanca
Salamanca, Spain
|
|
|
|
|
Angela Dispenzieri, MD
Mayo Clinic
Rochester, Minnesota
|
|
|
|
|
Faith E. Davies, MD
The Royal Marsden NHS Foundation Trust
Sutton, Surrey, UK
Member, IMF Board of Scientific Advisors
|
|
|
|
|
Jeffrey A. Zonder, MD
Karmanos Cancer Institute
Detroit, Michigan
|
|
|
|
|
Bahrat Aggarwal, PhD
MD Anderson Cancer Center
Houston, Texas
|
|
Transplantation
|
|
|
Jean Luc Harousseau, MD
Hematologie Clinique
CHU Hotel Dieu
Nantes, France
Member, IMF Board of Scientific Advisors
|
|
|
|
|
Benedetto Bruno, MD, PhD
San Giovanni Battista Hospital
University of Torino
Torino, Italy
|
|
|
|
|
Roman Hajek, MD
University Hospital Brno
Brno, Czech Republic
Member, IMF Board of Scientific Advisors
|
|
|
|
|
Patrizia Tosi, MD
Seràgnoli Institute of Hematology
Bologna, Italy
|
|
|
|
|
Meral Beksac, MD
Ankara University
Ibn Sina Hospital
Ankara, Turkey
Member, IMF Board of Scientific Advisors
|
|
|
|
|
Marco Ladetto, MD
Divisione Universitaria di Ematologia
L'università di Torino
Torino, Italy
|
|
|
|
|
Patrizia Tosi, MD
Seràgnoli Institute of Hematology
Bologna, Italy
|
|
|
|
|
Javier de la Rubia, MD
University Hospital La Fe
Valencia, Spain
|
|
|
|
|
Joan Bladé, MD
Hospital Clinic
Hematology
Barcelona, Spain
Member, IMF Board of Scientific Advisors
|
|
|
|
|
Hermann Einsele, MD
University Clinic of Würzburg
Würzburg, Germany
Member, IMF Board of Scientific Advisors
|
|
|
|
|
Peter Liebisch, MD
University Hospital of Ulm
Ulm, Germany
|
|
New Approaches
|
|
|
Herve Avet-Loiseau, MD
Institut de Biologie
Nantes, France
Member, IMF Board of Scientific Advisors
|
|
|
|
|
Orhan Sezer, MD
Medizinische Klinik und Poliklinik II
Berlin, Germany
Member, IMF Board of Scientific Advisors
|
|
|
|
|
Brian G.M. Durie, MD
Cedars Sinai Comprehensive Cancer Center
Los Angeles, California
Chairman, International Myeloma Foundation
|
|
|
|
|
Robert A. Kyle, MD
Mayo Clinic
Rochester, Minnesota
Chair, IMF Board of Scientific Advisors
|
|
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, MN
|
|
|
|
|
Andrzej Jakubowiak, MD
University of Michigan Cancer Center
Ann Arbor, MI
|
|
|
|
|
Robert A. Kyle, MD
Mayo Clinic
Rochester, Minnesota
Chairman, IMF Board of Scientific Advisors
|
|
|
|
|
Hartmut Goldschmidt, MD
Medizinischen Universitätsklinik und Poliklinik V
University of Heidelberg
Heidelberg, Germany
Member, IMF Board of Scientific Advisors
|
|
|
back
print